Skip to main content

JDRF has now rebranded to Breakthrough T1D.
Our name has changed, our mission has not.

Prevention research

JDRF and Helmsley Trust funding leads global research push to prevent type 1 diabetes

JDRF and the Helmsley Charitable Trust have announced over £1.5 million in joint funding for five international researchers – including one UK-based researcher – to access unique data sources and unravel how type 1 diabetes develops, with the goal of preventing the condition.
Breakthrough T1D profile picture
Josie Clarkson 13 February 2024

A profile photo of type 1 diabetes prevention researcher, Professor Claire Meek.

Professor Claire Meek at the University of Leicester is leading one of five global research projects receiving part of £1.5 million funding from JDRF and the Helmsley Charitable Trust to access a unique database which could help prevent type 1 diabetes.

Professor Meek is partnering with the Environmental Determinants of Islet Autoimmunity (ENDIA) Study. Pioneering in its approach, this study monitors close relatives of people with type 1, beginning when they are still in the womb, to investigate the intricate relationship between environmental factors and an individual’s genes. The primary goal is to unravel the role these factors play in initiating and influencing the development of type 1 diabetes.

What is the ENDIA Study?

ENDIA has collected over 200,000 unique biological samples – such as blood, immune cells, breast milk, nasal swabs, stool, and urine samples – along with 16 million medical observations from 1500 people with a parent or sibling diagnosed with type 1.

JDRF and Helmsley have supported ENDIA since 2015, and together we are now investing a further £1.5 million to allow five researchers around the world to collaborate with ENDIA. Professor Meek and the other select researchers will use ENDIA’s extensive resources to investigate novel concepts about how type 1 develops.

Dr Dorota Pawlak, Chief Scientific Officer at JDRF Australia, said: “ENDIA was the first study of its kind globally. The richness of the data and uniqueness of biological samples collected puts it at the forefront of research in type 1 diabetes prevention. This funding announcement will see ENDIA’s impact reach a new international level, by giving the best and brightest type 1 diabetes researchers around the globe access to ENDIA’s precious resources for innovative investigations seeking to uncover new findings. Importantly, it will also widen the scale of national and international expertise within the ENDIA team through these collaborations.”

What are the five new research projects?

New UK-based research project

Professor Meek will hunt for new ways to identify how likely individuals are to develop type 1 by using advanced techniques to identify biological changes during pregnancy that may alter the unborn baby’s pancreas and immunity. By comparing children with different exposures during pregnancy, Professor Meek aims to discover biological markers in newborn babies that could predict type 1.

Professor Claire Meek, who is working within the National Institute for Health and Care Research Leicester Biomedical Research Centre said: “I am delighted to be one of only five researchers across the world given exclusive access to ENDIA’s unique and unprecedented resources. I would like to thank JDRF and Helmsley for their longstanding commitment to unravelling the driving forces behind type 1 diabetes. I am honoured to contribute to the research by hunting for any pivotal biological changes that occur during pregnancy that may cause changes in the unborn child’s pancreas that could predict if they will develop type 1 diabetes. Along with the other four researchers receiving funding today, my project will bring us closer to being able to prevent type 1 diabetes.”

Pancreatic hormones and developing type 1

Insulin autoantibodies are biological markers that the immune attack on insulin-making beta cells has begun. Assistant Professor Clive Wasserfall from the University of Florida previously discovered that people with more than two types of insulin autoantibodies showed reduced levels of the growth hormones IGF1 and IGF2. In this project, Clive and his team will measure levels of IGF1, IGF2, and a digestive substance produced in the pancreas called trypsinogen in children, to determine if they can be used as early-life indicators of a person’s risk of developing type 1.

Maternal diabetes and the child’s risk of type 1

In her study at the University of Colorado, Assistant Professor Randi Johnson will look at how a mother’s type 1 diabetes during pregnancy reduces their baby’s risk of developing type 1. Focusing on specific changes to the DNA of the immune cells, Randi will investigate how maternal blood sugar control during pregnancy might impact the child’s susceptibility to type 1. She aims to understand these changes and potentially develop targeted therapies for individuals with a family history of type 1.

Breastmilk and risk of type 1

A mother’s breastmilk is influenced by her diet and whether she has diabetes. Dr Satvika Burugupalli at the Baker Heart & Diabetes Institute is seeking to understand if specific components in breastmilk can affect the risk of children developing insulin autoantibodies and type 1 diabetes. Satvika will analyse the bacteria, fats, sugars and other components of mothers’ breastmilk and compare them with the bacteria in the mouths of their infants. She hopes this will reveal any potential links between the composition of breastmilk and children developing type 1.

The role of gut microbes in type 1 diabetes

Associate Professor Tommi Vatanen from the University of Helsinki will build upon previous research on gut bacteria, known as the gut microbiome, in families. Tommi will collaborate with the ENDIA team to examine how gut bacteria may be related to the development of insulin autoantibodies and type 1 within families. Tommi and his team will assess the gut microbiomes of the family members of people with type 1 to identify patterns associated with autoimmunity. They will also use cutting-edge technology and analysis to investigate bacterial interactions, transmission, and the potential role of certain microbes in the development of type 1.

Bringing us closer to preventing type 1

Being able to accurately estimate who will develop type 1 will enable us to detect the onset of the condition earlier than ever before. Rachel Connor, Director of Research Partnerships at JDRF UK, said: “JDRF is proud to have supported ENDIA from its inception and it is incredibly exciting to announce this first round of research projects to delve into its fantastic data.

“It is more exciting still that one of these five pioneering research projects is taking place here in the UK. Through innovative research projects like Professor Claire Meek’s, we hope to reach a point where we can stop type 1 diabetes in its tracks, so that people never experience the burden of managing type 1 diabetes with insulin and we can consign this condition to the history books.”

You may also be interested in

Read more
Two researchers in a lab

Our prevention research

Discover our research to prevent type 1 diabetes.

Read more
Sergio Pedraza, type 1 diabetes researcher, in the lab

Current research projects

Find out about the JDRF-funded research projects in the UK.

Read more
Young Alfie with his Mum and Dad

Donate now

Donate now to help fund our ground-breaking research.

Connect with us on social

Related news

Read more
Mum and daughter wearing Breakthrough T1D t-shirts and holding a flag in a park.
News
16 December 2024

Research and policy breakthroughs in 2024

Our highlights from a year full of breakthroughs in type 1 diabetes research and advocacy.

Read more
A photograph of two women. The woman on the right is a healthcare professional who has a hand on the other woman's arm.
Research
12 November 2024

New policy framework launches to improve sex and gender data in UK research

The framework aims to encourage UK researchers to consider different sexes (biological attributes) and genders (roles, behaviours and identity in society) to address gaps in health data.

Read more
A young woman wearing a continuous glucose monitor looks on to a man scanning his sensor.
News
29 October 2024

New report calls for more equal access to type 1 diabetes technology

Our Access for All report, launched today, highlights how far we’ve come with advancements in diabetes technology, but shows that many people still face barriers when trying to access T1D technology.

Read more
A researcher sits in a lab beside screening samples and lab equipment for early detection of type 1 diabetes.
Research
24 June 2024

New guidance sets out how to support people with early-stage type 1 diabetes

New international guidance detailing how to monitor and support people with early-stage type 1 diabetes (T1D) has the potential to reduce the trauma associated with being diagnosed with T1D, enable people to access the latest treatments to delay the need for insulin therapy, and reduce long-term health complications.